The Most Read Scientific Articles of October in Interventional Cardiology

1- Incidence and Prognosis of Heart Valve Embolization

The incidence of peri-procedural transcatheter heart valve embolization and migration (TVEM) is as low as 1%. However, it is associated with increased morbidity and mortality.

Read more HERE

2- 1000 MitraClips: Results from the World’s Most Experienced Site

In September 2008, interventional physicians at the Heart and Vascular Centre Hamburg conducted the first MitraClip implantation after its Conformité Européenne (CE)-marking approval. In July 2019, the same site reached an amazing milestone, 1000 MitraClips implanted, and in doing so it became the most experienced site in the world.

Read more HERE

3- SOLACI Interviews | Dr. Carla Agatiello: “The aim of Grupo MIL is to create a collaboration network of women across Latin America”

The predominance of women in the world is an uncontested reality that is causing changes in different aspects of daily life. In the world of interventional cardiology, the number of women compared to men has always been very low. However, this process is slowly beginning to change because more and more women are showing their interest in our specialty.

Read more HERE

4- See the 2019 Panama Sessions presentations

The XXXIX Regional SOLACI Sessions in Panama were an extremely successful scientific event. Renowned specialists in hemodynamics from all over Latin America presented their works and shared their knowledge in an event characterized by the utmost respect and comradeship.

Read more HERE

5- Subintimal vs. Intraplaque Coronary Rechanneling. Do Results Vary?

Coronary rechanneling is difficult by nature, and there are several techniques for it aimed at improving technical success. Some of these strategies entail the subintimal crossing of the occluded segment, while others entail intraplaque crossing, without leaving the true lumen. However, there is scarce or no information on the results of both strategies.

Read more HERE

6- TAVR Offers Better Quality of Life to Low Risk Patients

As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year. 

Read more HERE

7- TCT 2019 | PCI in Stable CAD. Prior TAVR, with TAVR or Never?

This interesting study presented at TCT 2019 and simultaneously published in Am J Cardiol tells us PCI in stable coronary artery disease cannot lower risk in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR).

Read more HERE

8- TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment.

Read more HERE

9- Meta-Analysis of Large TAVR Studies on Low-Risk: Evidence is Consistent

This meta-analysis which included the 4 large randomized studies on transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) in low-risk patients recently published in JACC, showed TAVR is associated with significant lower mortality compared against SAVR at one year follow up. 

Read more HERE

10- TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information.

Read more HERE



Would you like to receive a weekly summary of the most recent scientific articles?

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

*

Top